Abstract
Interleukin-1 beta (IL1) and tumor necrosis factor alpha (TNF) promote non-rapid eye movement sleep under physiological and inflammatory conditions. Additional cytokines are also likely involved but evidence is insufficient to conclude that they are sleep regulatory substances. Many of the symptoms induced by sleep loss, e.g. sleepiness, fatigue, poor cognition, enhanced sensitivity to pain, can be elicited by injection of exogenous IL1 or TNF. We propose that ATP, released during neurotransmission, acting via purine P2 receptors on glia releases IL1 and TNF. This mechanism may provide the means by which the brain keeps track of prior usage history. IL1 and TNF in turn act on neurons to change their intrinsic properties and thereby change input-output properties (i.e. state shift) of the local network involved. Direct evidence indicates that cortical columns oscillate between states, one of which shares properties with organism sleep. We conclude that sleep is a local use-dependent process influenced by cytokines and their effector molecules such as nitric oxide, prostaglandins and adenosine.
Keywords: Local sleep, interleukin, TNF, neurotrophin, adenosine, purine P2 receptors
Current Pharmaceutical Design
Title: The Role of Cytokines in Sleep Regulation
Volume: 14 Issue: 32
Author(s): James M. Krueger
Affiliation:
Keywords: Local sleep, interleukin, TNF, neurotrophin, adenosine, purine P2 receptors
Abstract: Interleukin-1 beta (IL1) and tumor necrosis factor alpha (TNF) promote non-rapid eye movement sleep under physiological and inflammatory conditions. Additional cytokines are also likely involved but evidence is insufficient to conclude that they are sleep regulatory substances. Many of the symptoms induced by sleep loss, e.g. sleepiness, fatigue, poor cognition, enhanced sensitivity to pain, can be elicited by injection of exogenous IL1 or TNF. We propose that ATP, released during neurotransmission, acting via purine P2 receptors on glia releases IL1 and TNF. This mechanism may provide the means by which the brain keeps track of prior usage history. IL1 and TNF in turn act on neurons to change their intrinsic properties and thereby change input-output properties (i.e. state shift) of the local network involved. Direct evidence indicates that cortical columns oscillate between states, one of which shares properties with organism sleep. We conclude that sleep is a local use-dependent process influenced by cytokines and their effector molecules such as nitric oxide, prostaglandins and adenosine.
Export Options
About this article
Cite this article as:
Krueger M. James, The Role of Cytokines in Sleep Regulation, Current Pharmaceutical Design 2008; 14 (32) . https://dx.doi.org/10.2174/138161208786549281
DOI https://dx.doi.org/10.2174/138161208786549281 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design Outcomes of Patients with Chronic Heart Failure and Iron Deficiency Treated with Intravenous Iron: A Meta-analysis
Cardiovascular & Hematological Disorders-Drug Targets Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Membrane and Soluble Forms of Endoglin in Preeclampsia
Current Molecular Medicine Anesthesia Issues in Central Nervous System Disorders
Current Aging Science Novel Targets for Cardiac Antiarrhythmic Drug Development
Current Pharmaceutical Design Role of Bradykinin in the Regulation of Endothelial Nitric Oxide Synthase Expression by Cardiovascular Drugs
Current Pharmaceutical Design Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design Possible Therapeutic Targets in Cardiac Myocyte Apoptosis
Current Pharmaceutical Design Increased Exercise Favorably Modifies Coronary Artery Disease and Peripheral Arterial Disease Outcomes
Current Vascular Pharmacology The Role of the Osteoprotegerin/RANKL/RANK System in Diabetic Vascular Disease
Current Medicinal Chemistry Peptide and Non-peptide Antagonists Targeting Endothelin Receptors in Physiology and Pathology
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptors: Role of Isoform Gamma in the Antineoplastic Effect of Iodine in Mammary Cancer
Current Cancer Drug Targets Dietary Prevention of Coronary Heart Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Therapeutic Efficacy of Selegiline in Neurodegenerative Disorders and Neurological Diseases
Current Drug Targets Clinical Characteristics and Treatment of Cardiomyopathies in Children
Current Cardiology Reviews Biomarkers of Oxidative Stress and Cataract. Novel Drug Delivery Therapeutic Strategies Targeting Telomere Reduction and the Expression of Telomerase Activity in the Lens Epithelial Cells with N-Acetylcarnosine Lubricant Eye Drops: Anti-Cataract which Helps to Prevent and Treat Cataracts in the Eyes of Dogs and other Animals
Current Drug Delivery Endothelial Dysfunction in Morbid Obesity
Current Pharmaceutical Design Prader-Willi Syndrome: Clinical Genetics and Diagnostic Aspects with Treatment Approaches
Current Pediatric Reviews